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• Hearts treated with autophagy enhancers as pre-treatment or post-
treatment both showed a decrease in infarct size percentage and an 
increase in cardiac function when compared to control I/R group.
• Hearts treated with an autophagy inhibitor as pre-treatment or post-
treatment did not show a significant decrease in infarct size, and cardiac 
function was compromised similar as control I/R group.
The results suggest enhancement of autophagy may mitigate reperfusion 
injury when given as either pre or post-treatment.
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Experimental groups consisted of:
 Control I/R (n=9)
o No drug infused
 Autophagy Enhancer
o 25nM Rapamycin (Rapa.) (n=5)




o 1mM 3-Methyladenine (3-MA)
 Pre-treatment (n=6)
 Post-treatment (n=5)
All animal procedures were in accordance with Philadelphia College of Osteopathic 
Medicine rules and regulations. Cardiac function was measured by placing a pressure 
transducer into the left ventricle of the isolated rat heart and the data was recorded using 
Powerlab Station acquisition software. The cardiac parameters of importance included: final 
left ventricular end systolic pressure (LVESP), final left ventricular end diastolic pressure 
(LVEDP), final left ventricular developed pressure (LVDP=LVESP-LVEDP) and the 
minimal rate of LVDP relaxation (-dP/dt min).
All data in the text and figures are presented as means ± standard error. Cardiac function 
and TTC staining data was analyzed by ANOVA using post hoc analysis with Student-
Newman-Keuls test. Probability values of p<0.05 were considered statistically significant 
and represented by an asterisk (*) as previously described (4).
Methods
Background
Coronary Heart Disease (CHD) is the leading cause of death and disability worldwide, 
claiming about 600,000 deaths in the United States each year (1). The most severe problem 
occurring in CHD is caused by plaque accumulation that leads to ischemia, chest pain, and 
ultimately myocardial infarction (1). The best treatment is timely and effective reperfusion via 
angioplasty to salvage heart tissue and decrease infarct size. 
However, reperfusion can cause additional injury to the heart, which is termed “reperfusion 
injury”.  The strategy to reduce reperfusion injury to preserve more cardiac function of the 
patients is under active investigation. Our research focuses on understanding the relationship 
between autophagy and myocardial ischemia/reperfusion (I/R) injury. 
Autophagy is a housekeeping process used to degrade protein aggregates and damaged 
cytoplasmic constituents when cells go through a nutrient stress (2). Research has shown that 
autophagy enhancement before ischemia (i.e. pre-treatment) is beneficial to cardiac function 
(3). However, a debate persists on whether autophagy is beneficial to attenuate or promote cell 
damage at the beginning of reperfusion (i.e. post-treatment) (see figure 1). This study tested the 
effects of an autophagy enhancer (e.g. rapamycin and trehalose) and inhibitor (e.g. 3-
methyladenine) on heart function and infarct size after global I/R in isolated rat hearts.
Figure 1. The possible role of autophagy during I/R (1).
Objective
To investigate if autophagy is beneficial or detrimental to myocardial I/R injury by measuring 
post-reperfused cardiac function and infarct size when giving autophagy enhancers or inhibitor 
as either pre-treatment or post-treatment compared to control I/R group.
Hypothesis
Autophagy enhancement would be beneficial to cardiac function and decrease infarct size 
when given as post-treatment similar to pre-treatment when compared to control I/R. By 
contrast, autophagy inhibition would exhibit compromised cardiac function and similar infarct 
percentage as control I/R. 
Conclusions & Implications
Future investigations will include:
• Evaluation of the synergistic effects of autophagy enhancers on cardiac 
function and infarct size when given as both pre and post-treatment.
• Evaluate the change of the autophagy induction markers by measuring 
LC3-2 and Beclin-1 (see figure 9) in an isolated hypoxia/re-
oxygenation cardiomyocyte model.
• Evaluate the effects of autophagy enhancers or inhibitors in isolated 
hypoxia/ re-oxygenation cardiomyocytes model. 













Figure 3. Initial and final levels of LVESP among all groups. Initial LVESP among 
all groups were similar. Compared to final LVESP in control I/R group, autophagy 
enhancer and inhibitor did not show significant difference. 
Figure 4. Initial and final LVEDP levels among all groups. Control I/R group 
showed a very high final LVEDP level. By contrast, autophagy enhancement as pre 
or post-treatment showed a decrease in final LVEDP compared to that of  control 
I/R; rapamycin pre-treatment showed the lowest final LVEDP (p<0.05). However, 
autophagy inhibition as pre or post-treatment (3-MA) did not reduce final LVEDP 
compared to control I/R group.
Figure 5. Initial and final levels of –dP/dt min among all groups. Control I/R group showed 
a very low final -dP/dt min level. By contrast, autophagy enhancement as pre or post-
treatment showed significantly better rate of pressure change when compared to control I/R 
(p<0.05). However, autophagy inhibition as pre or post-treatment did not improve final 
-dP/dt min when compared to control I/R.
Figure 6. Initial and final levels of LVDP among all groups.  Control I/R showed 
a decrease in final LVDP. By contrast, autophagy enhancement as pre or post-
treatment showed an increase in final LVDP when compared to control I/R 
(p<0.05). Rapamycin pre-treatment had the highest final LVDP value. However, 
autophagy inhibition as pre or post-treatment did not improve final LVDP when 
compared to control I/R.
Figure 8. Infarction percentage among all groups. Control I/R had a high infarct 
percentage of 39 ± 4%. By contrast, autophagy enhancement as pre or post-treatment 
showed a significant decrease in infarct percentage compared to control I/R (p<0.05). 
Rapamycin pre-treatment had the lowest infarct percentage. Autophagy inhibition as pre or 
post-treatment also showed a similar infarct percentage as control I/R. 
PRE-treatment (for 5 minutes at a rate of 
1mL/min)
POST-treatment (for 5 minutes at a rate of 
1mL/min)
Figure 7. Representative sectional slice of heart after 1% TTC staining 
among all groups. The brick red staining indicated viable cardiac tissue 
whereas the white area indicated non-viable cardiac tissue. By contrast to 
control I/R and 3-MA treatment (autophagy inhibitor), the autophagy 
enhancers reduced infarct area when given as pre or post-treatment.
Figure 9. Signaling pathway involved upregulation of Beclin-1 and 































Left Ventricular End Systolic Pressure (LVESP)
Initial
Final
Control I/R      Rap  Pre      Rap Post    Treh Pre       Treh Post      3-MA Pre     3-MA Post






























Control I/R 25nM rapamycin PREtreatment 5min
25nM rapamycin POSTtreatment 5min 5mM trehalose PREtreatment for 5min
5mM trehalose POSTtreatment for 5min 1mM 3MA PREtreatment for 5min
1mM 3MA POSTtreatment for 5min
*
*










































































Control I/R      Rapa Pre      Rapa Post    Treh Pre   Treh Post     3-MA Pre   3-MA Post
Control I/R      Rap  Pre      Rapa Post    Treh Pre       Treh Post   3-MA Pre     3-MA Post
A. Control I/R B. Rapa. Pre-treatment C. Rapa. Post-treatment




































Rate of Pressure Change
Initial
Final
Control I/R      Rapa Pre      Rapa Post    Treh Pre       Treh Post      3-MA Pre     3-MA Post
* * * *
Figure 2a. Flow Diagram of experimental protocol
Figure 2b. Langendorff Apparatus used for 
isolated heart.
